home / stock / bctx / bctx news

BCTX News and Press, BriaCell Therapeutics Corp. From 12/02/22

Stock Information
Company Name: BriaCell Therapeutics Corp.
Stock Symbol: BCTX
Market: NASDAQ
Website: briacell.com
Menu
BCTX BCTX Quote BCTX Short BCTX News BCTX Articles BCTX Message Board
Get BCTX Alerts

News, Short Squeeze, Breakout and More Instantly...
BCTX - BriaCell’s Lead Candidate Bria-IMT™ Shows Promising Results For Advanced Breast Cancer Patients

(NewsDirect) The world of biotech is having what some are calling a golden age . Many companies are presenting new and innovative drugs to the FDA for approval and later the public for consumption. Smart Beta EFTs like SPDR S&P Biotech (NYSEARCA: XBI) (“XBI”)...
BCTX - IPA's Subsidiary BioStrand and BriaCell Announce Artificial Intelligence Collaboration and License Agreement to Discover and Develop Anti-Cancer Antibodies

IPA (IMMUNOPRECISE ANTIBODIES LTD.) ( “IPA”) (NASDAQ: IPA), an advanced biotherapeutic research and technology company, today announced that BioStrand BV (“BioStrand”), an AI in silico discovery subsidiary of IPA, has entered into a research collaboration and licen...

BCTX - BriaCell CEO Discusses Positive Clinical Results of its Breast Cancer Immunotherapy Treatment in an Audio Interview with SmallCapVoice.com

AUSTIN, Texas, Nov. 15, 2022 (GLOBE NEWSWIRE) -- SmallCapVoice.com Inc. (“SCV”) announces the availability of a new audio interview with Dr. Bill Williams, CEO of BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V: BCT), to discuss the positive initial efficacy data of t...

BCTX - BriaCell Reports Positive Breast Cancer Efficacy Data with Bria-IMT(TM) Immunotherapy Treatment at SITC Annual Meeting

Bria-IMT™ regimen in combination with Incyte’s retifanlimab produced evidence of disease control, tumor shrinkage, and potential survival benefit amongst BriaCell’s recent 12 patient cohort in advanced breast cancer. The regimen remains well tolerated ...
BCTX - BriaCell Announces Successful Completion of Phase I Portion of Clinical Study in Advanced Breast Cancer; Randomized Phase II Efficacy Evaluation Progressing

BriaCell has successfully completed its Phase I safety and tolerability evaluation of Bria-IMT™ in combination with Incyte’s retifanlimab in advanced breast cancer. The combination treatment showed a favorable safety profile in 12 patients. Phase ...

BCTX - BriaCell Announces New Clinical Trial Site to Bring Novel Cancer Treatments to Advanced Breast Cancer Patients

PHILADELPHIA and VANCOUVER, British Columbia, Oct. 12, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”) , a clinical-stage biotechnology company specializing in targeted immunotherapies for ca...

BCTX - BriaCell to Present New Clinical Data at the 2022 San Antonio Breast Cancer Symposium® December 6th and 7th

PHILADELPHIA and VANCOUVER, British Columbia, Sept. 28, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”) , a clinical-stage biotechnology company specializing in targeted immunotherapies for c...
BCTX - BriaCell Partners with Caris Life Sciences® to Expand Patient Outreach and Molecular Profiling

PHILADELPHIA and VANCOUVER, British Columbia, Sept. 14, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”) , a clinical-stage biotechnology company specializing in targeted immunotherapies for c...

BCTX - BriaCell Announces Presentation at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting

PHILADELPHIA and VANCOUVER, British Columbia, Sept. 07, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”) , a clinical-stage biotechnology company specializing in targeted immunotherapies for c...

BCTX - BriaCell stock rises on license deal for anti-cancer agent

BriaCell Therapeutics ( NASDAQ: BCTX ) stock rose 5% on Aug. 4 after the company said it secured an exclusive license from University of Maryland, Baltimore County (UMBC) to develop and commercialize Soluble CD80 (sCD80) as a biologic agent to treat cancer. In animal ...
Previous 10 Next 10